A clinical trial to learn how an investigational drug (norucholic acid) is absorbed, distributed, broken down, and removed from the body when given to people with kidney problems
Phase 1
Recruiting
- Conditions
- onalcoholic fatty liver disease (NAFLD), Primary sclerosing cholangitis (PSC)MedDRA version: 22.0Level: LLTClassification code: 10029530Term: Non-alcoholic fatty liver Class: 10019805MedDRA version: 20.1Level: LLTClassification code: 10036732Term: Primary sclerosing cholangitis Class: 10019805MedDRA version: 22.0Level: PTClassification code: 10053219Term: Non-alcoholic steatohepatitis Class: 100000004871Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
- Registration Number
- CTIS2023-505862-27-00
- Lead Sponsor
- Dr. Falk Pharma GmbH
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 48
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method